Yunnan Baiyao Group Co Ltd Asset Resilience Ratio
Yunnan Baiyao Group Co Ltd asset resilience ratio. Yunnan Baiyao Group Co Ltd (000538) has an Asset Resilience Ratio of 8.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000538 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Yunnan Baiyao Group Co Ltd (1993–2024)
Asset resilience ratio of Yunnan Baiyao Group Co Ltd from 1993 to 2024. This chart shows how Yunnan Baiyao Group Co Ltd's Asset Resilience Ratio has changed over time. Read Yunnan Baiyao Group Co Ltd (000538) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Yunnan Baiyao Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 000538 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥4.47 Billion | 8.38% |
| Total Liquid Assets | CN¥4.47 Billion | 8.38% |
Asset Resilience Insights
- Limited Liquidity: Yunnan Baiyao Group Co Ltd maintains only 8.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yunnan Baiyao Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Yunnan Baiyao Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Yunnan Baiyao Group Co Ltd Asset Resilience Ratio by Year (1993–2024)
Yunnan Baiyao Group Co Ltd asset resilience ratio by year from 1993 to 2024. The table below shows the annual Asset Resilience Ratio data for Yunnan Baiyao Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.81% | CN¥2.55 Billion ≈ $372.72 Million |
CN¥52.91 Billion ≈ $7.74 Billion |
+4.54pp |
| 2023-12-31 | 0.28% | CN¥149.37 Million ≈ $21.86 Million |
CN¥53.78 Billion ≈ $7.87 Billion |
-4.25pp |
| 2022-12-31 | 4.53% | CN¥2.42 Billion ≈ $353.50 Million |
CN¥53.32 Billion ≈ $7.80 Billion |
-4.50pp |
| 2021-12-31 | 9.03% | CN¥4.72 Billion ≈ $690.71 Million |
CN¥52.29 Billion ≈ $7.65 Billion |
-11.31pp |
| 2020-12-31 | 20.33% | CN¥11.23 Billion ≈ $1.64 Billion |
CN¥55.22 Billion ≈ $8.08 Billion |
+2.57pp |
| 2019-12-31 | 17.76% | CN¥8.82 Billion ≈ $1.29 Billion |
CN¥49.66 Billion ≈ $7.27 Billion |
-6.15pp |
| 2018-12-31 | 23.92% | CN¥7.26 Billion ≈ $1.06 Billion |
CN¥30.38 Billion ≈ $4.45 Billion |
-0.45pp |
| 2017-12-31 | 24.36% | CN¥6.75 Billion ≈ $987.65 Million |
CN¥27.70 Billion ≈ $4.05 Billion |
+16.22pp |
| 2016-12-31 | 8.14% | CN¥2.00 Billion ≈ $293.00 Million |
CN¥24.59 Billion ≈ $3.60 Billion |
-7.62pp |
| 2015-12-31 | 15.77% | CN¥3.04 Billion ≈ $445.07 Million |
CN¥19.29 Billion ≈ $2.82 Billion |
+13.10pp |
| 2014-12-31 | 2.67% | CN¥436.37 Million ≈ $63.85 Million |
CN¥16.34 Billion ≈ $2.39 Billion |
+2.67pp |
| 2013-12-31 | 0.00% | CN¥149.76K ≈ $21.91K |
CN¥12.88 Billion ≈ $1.88 Billion |
0.00pp |
| 2011-12-31 | 0.01% | CN¥519.68K ≈ $76.05K |
CN¥9.09 Billion ≈ $1.33 Billion |
-0.02pp |
| 2006-12-31 | 0.03% | CN¥587.23K ≈ $85.93K |
CN¥2.19 Billion ≈ $320.67 Million |
+0.01pp |
| 2005-12-31 | 0.01% | CN¥239.41K ≈ $35.03K |
CN¥1.60 Billion ≈ $234.20 Million |
-0.08pp |
| 2004-12-31 | 0.09% | CN¥1.19 Million ≈ $174.33K |
CN¥1.27 Billion ≈ $185.96 Million |
+0.07pp |
| 2003-12-31 | 0.02% | CN¥248.88K ≈ $36.42K |
CN¥1.05 Billion ≈ $153.02 Million |
-0.01pp |
| 2002-12-31 | 0.03% | CN¥306.44K ≈ $44.84K |
CN¥920.65 Million ≈ $134.72 Million |
-0.02pp |
| 2001-12-31 | 0.05% | CN¥416.78K ≈ $60.99K |
CN¥843.99 Million ≈ $123.50 Million |
-0.77pp |
| 2000-12-31 | 0.82% | CN¥6.53 Million ≈ $955.00K |
CN¥792.85 Million ≈ $116.02 Million |
+0.66pp |
| 1999-12-31 | 0.16% | CN¥1.25 Million ≈ $183.46K |
CN¥761.62 Million ≈ $111.45 Million |
-0.71pp |
| 1998-12-31 | 0.88% | CN¥3.09 Million ≈ $452.77K |
CN¥351.99 Million ≈ $51.51 Million |
+0.70pp |
| 1997-12-31 | 0.18% | CN¥565.84K ≈ $82.80K |
CN¥315.44 Million ≈ $46.16 Million |
-7.32pp |
| 1996-12-31 | 7.50% | CN¥19.45 Million ≈ $2.85 Million |
CN¥259.26 Million ≈ $37.94 Million |
-19.63pp |
| 1995-12-31 | 27.14% | CN¥66.80 Million ≈ $9.77 Million |
CN¥246.17 Million ≈ $36.02 Million |
-2.89pp |
| 1994-12-31 | 30.03% | CN¥60.30 Million ≈ $8.82 Million |
CN¥200.83 Million ≈ $29.39 Million |
+16.98pp |
| 1993-12-31 | 13.05% | CN¥23.00 Million ≈ $3.37 Million |
CN¥176.27 Million ≈ $25.79 Million |
-- |
About Yunnan Baiyao Group Co Ltd
Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China. The company offers health products; drugs; chemical raw materials, chemical preparations, sales of chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, biological products, medical devices, health food, food, beverages, special labor protection products, production and sales … Read more